Eagle Health Investments LP Purchases Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE

Eagle Health Investments LP purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 884,121 shares of the biopharmaceutical company’s stock, valued at approximately $29,521,000. Ultragenyx Pharmaceutical makes up 4.9% of Eagle Health Investments LP’s holdings, making the stock its 9th biggest holding.

Several other large investors also recently made changes to their positions in RARE. Jefferies Financial Group Inc. acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth $10,973,000. BNP Paribas Financial Markets raised its stake in shares of Ultragenyx Pharmaceutical by 57.6% in the 4th quarter. BNP Paribas Financial Markets now owns 903,050 shares of the biopharmaceutical company’s stock valued at $20,770,000 after purchasing an additional 330,031 shares during the period. GW&K Investment Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 19.6% in the fourth quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock valued at $31,634,000 after purchasing an additional 225,238 shares in the last quarter. UBS Group AG lifted its holdings in shares of Ultragenyx Pharmaceutical by 22.3% in the fourth quarter. UBS Group AG now owns 668,811 shares of the biopharmaceutical company’s stock valued at $15,383,000 after purchasing an additional 121,786 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after buying an additional 131,087 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 2.9%

NASDAQ:RARE opened at $26.24 on Thursday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $39.89. The firm has a fifty day simple moving average of $28.52 and a 200 day simple moving average of $24.96. The stock has a market capitalization of $2.59 billion, a PE ratio of -4.49 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.12 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the sale, the chief financial officer owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This trade represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,552 shares of company stock worth $207,455 in the last ninety days. Insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Barclays decreased their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Monday, August 10th. Cantor Fitzgerald lifted their price objective on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, May 21st. Finally, Wedbush cut their price objective on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.82.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.